Following U.S. Stocks are among the “Most Active” Stocks in the course of recent trading session, Thursday: HRG Group Inc (NYSE:HRG), Exelixis, Inc (NASDAQ:EXEL), Entropic Communications, Inc (NASDAQ:ENTR), Halliburton Company (NYSE:HAL)

• HRG Group Inc (NYSE:HRG), with shares raised 3.31% is now trading at $12.47. The Stock is active as 3.53M shares changed hands as compared to its average volume of 451,105.00 shares.

• Exelixis, Inc (NASDAQ:EXEL), with shares declined -10.41% is now trading at $2.62. The Stock is active as 2.84M shares changed hands as compared to its average volume of 5.10M shares.

• Entropic Communications, Inc (NASDAQ:ENTR) with shares improved 2.05% is now trading at $2.98. The Stock is active as 2.43M shares changed hands as compared to its average volume of 2.20M shares.

• Halliburton Company (NYSE:HAL), with shares dipped -0.34% is now trading at $41.16. The Stock is active as 3.52M shares changed hands as compared to its average volume of 15.40M shares.

Latest NEWS regarding these Stocks are depicted underneath:

HRG Group, Inc. (NYSE:HRG)

HRG Group, Inc. (HRG), declared that on March 6, 2015 it designated Omar Asali, its President, to the additional position of Chief Executive Officer. The Corporation also declared that it has changed its name to HRG Group, Inc. with shares ongoing to trade under the ticker “HRG.” Trading under the new name is started on March 11, 2015.

The Corporation’s Board of Directors noted: “After a thorough review, the Board elected Omar Asali to lead HRG forward as CEO.” Mr. Asali said, “I am grateful for the opportunity and look forward to leading the Corporation in the next stage of its development.”

Mr. Asali has been President and a Director of the Corporation since 2011. From 2009 to 2011 he was a Managing Director at Harbinger Capital Partners LLC, responsible for global portfolio strategy and business development. Preceding to that, Mr. Asali was at Goldman Sachs where he was most recently co-head of Goldman Sachs Hedge Fund Strategies and co-chair of its Investment Committee.

HRG Group, Inc., through its auxiliaries, provides various branded consumer products. The corporation operates in four segments: Consumer Products, Insurance, Energy, and Financial Services.

Exelixis, Inc. (NASDAQ:EXEL)

Formerly on February 24, Exelixis, Inc. (EXEL), stated financial results for the fourth quarter and full year of 2014 and offered an update on progress toward delivering upon its 2015 key corporate objectives and clinical development milestones.

Corporate Updates and Key Priorities for 2015

In 2015, Exelixis will continue to focus its development efforts and financial resources on the opportunities for cabozantinib in metastatic renal cell carcinoma (mRCC) and advanced hepatocellular carcinoma (HCC), and to support its partner Genentech, a member of the Roche Group, as it prepares for the potential worldwide commercialization of cobimetinib, a second Exelixis-discovered compound.

Top-Line Results for METEOR Trial in mRCC Predictable in Q2 2015. The corporation’s top clinical development precedingity is the delivery of top-line data for METEOR, the phase 3 pivotal trial of cabozantinib in mRCC. Enrollment in METEOR was accomplished in November 2014, and Exelixis anticipates top-line results from the trial’s primary endpoint, progression-free survival (PFS), in the second quarter of this year. Per the trial protocol, the primary PFS endpoint analysis will be conducted once 259 events have occurred among the first 375 patients enrolled. Enrollment for the first 375 patients in METEOR was accomplished in June 2014.

Cobimetinib U.S. and EU Regulatory Progress. As declared earlier this month, the U.S. Food & Drug Administration (FDA) has accepted for review Genentech’s New Drug Application (NDA) for cobimetinib, an Exelixis-discovered compound, to be used in combination with vemurafenib as a treatment for patients with BRAF V600 mutation-positive advanced melanoma. The FDA granted Precedingity Review to the NDA and assigned a Prescription Drug User Fee Act Action Date of August 11, 2015. Cobimetinib is the subject of a worldwide co-development contract between Exelixis and Genentech. Following this contract, Exelixis is entitled to an initial equal share of U.S. profits and losses, which share will decrease as sales raise. The parties will share equally in the U.S. marketing and commercialization costs, and, if approved, Exelixis will co-promote the compound in the U.S. Outside the U.S., Exelixis is entitled to receive royalties on sales of cobimetinib. In the European Union, Roche filed a Marketing Authorization Application for cobimetinib used in combination with vemurafenib in September of 2014.

Genentech has also initiated a series of early clinical studies evaluating the potential of cobimetinib in combination with other compounds in its oncology pipeline, counting the anti-PDL1 antibody MPDL3280A, and in other solid tumor types, counting non-small cell lung cancer (NSCLC), colorectal cancer and triple-negative breast cancer.

Exelixis, Inc. is a biopharmaceutical corporation committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ® (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, cobimetinib, a highly selective inhibitor of MEK, is being evaluated by Roche and Genentech (a member of the Roche Group) in a broad development program under a partnershipwith Exelixis.

Entropic Communications, Inc. (NASDAQ:ENTR)

Formerly on February 27, MaxLinear, Inc. (MXL) and Entropic Communications, Inc. (ENTR), declared that the U.S. Federal Trade Commission (FTC) has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to MaxLinear’s pending attainment of Entropic.

As formerly declared on February 3, 2015, MaxLinear and Entropic reached a definitive contract under which MaxLinear would attain Entropic for (i) $1.20 per share in cash and (ii) 0.2200 of a share of MaxLinear ordinary stock for each Entropic ordinary share outstanding. Termination of the HSR Act waiting period satisfies one of the conditions to closing of the projected transaction. The closing of the transaction is also subject to approval of the stockholders of both MaxLinear and Entropic, and other closing conditions, counting the effectiveness of MaxLinear’s Registration Statement on Form S-4. Subject to the satisfaction of these other conditions, the transaction is predictable to close in the second quarter of 2015.

Entropic(TM) is a world leader in semiconductor solutions for the connected home. The Corporation transforms how traditional HDTV broadcast and IP-based streaming video content is seamlessly, reliably, and securely delivered, processed, and distributed into and throughout the home.

Halliburton Corporation (NYSE:HAL)

Halliburton Corporation (HAL), is trading in a range of $41.06 - $41.67, while its 52-week highest price is $74.33, and its lowest hit in an year is $37.21. The stock opened its trade from $41.67. Its beta value is 0.89, however its one-year target price is $48.07.

Halliburton Corporation provides a range of services and products to the upstream oil and natural gas industry worldwide. The corporation operates through two segments, Completion and Production, and Drilling and Evaluation.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content comprised of in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve talk aboutions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as anticipates, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.